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As renal lipotoxicity can lead to chronic kidney disease (CKD),
we examined the role of peroxisome proliferator-activated
receptor (PPAR)-a, a positive regulator of renal lipolysis.
Feeding mice a high-fat diet induced glomerular injury, and
treating them with fenofibrate, a PPARa agonist, increased
the expression of lipolytic enzymes and reduced lipid
accumulation and oxidative stress in glomeruli, while
inhibiting the development of albuminuria and glomerular
fibrosis. In mice given an overload of free fatty acid-bound
albumin to induce tubulointerstitial injury, fenofibrate
attenuated the development of oxidative stress, macrophage
infiltration, and fibrosis, and enhanced lipolysis in the renal
interstitium. Fenofibrate inhibited palmitate-induced
expression of profibrotic plasminogen activator inhibitor-1
(PAI-1) in cultured mesangial cells, and the expression of
both monocyte chemoattractant protein-1 and PAI-1 in
proximal tubular cells along with the overexpression of
lipolytic enzymes. Thus, fenofibrate can attenuate
lipotoxicity-induced glomerular and tubulointerstitial injuries,
with enhancement of renal lipolysis. Whether amelioration of
renal lipotoxicity by PPARa agonists will turn out to be a
useful strategy against CKD will require direct testing.
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The prevalence of chronic kidney disease (CKD) and
subsequent end-stage kidney disease continues to increase
worldwide, despite the application of various intensive therapy
programs such as antihypertensive therapy.1 Thus, the estab-
lishment of new therapeutic strategies is urgently required.
Lipotoxicity is an important pathogenic process in several
types and stages of CKD.2,3 Lipotoxicity in glomeruli is
involved in the initiation of glomerular damage related to
obesity and type 2 diabetes.4,5 Glomerular lesion such as
glomerulosclerosis and albuminuria are observed in the early
stage of kidney disease associated with metabolic abnormal-
ities. We and others have shown that intrarenal lipotoxicity
resulting from enhanced renal lipogenesis and suppressed
renal lipolysis contributes to the development of glomerular
lesions in several animal experimental models, such as high-
fat diet (HFD)-induced obese mice6 and type 2 diabetic db/db
mice.7 Thus, therapeutic measures to combat lipolysis in
glomerular cells may be beneficial in glomerular injury
associated with metabolic syndrome or obesity.
Another type of lipotoxicity is related to the development of
tubulointerstitial lesion in proteinuric kidney disease regardless
of metabolic syndrome and obesity.8 The reuptake of free fatty
acid (FFA)-bound albumin, which is filtrated through the
glomeruli, has been demonstrated to mediate tubulointerstitial
damage in proteinuric kidney disease.9,10 As the progressive
nature of proteinuric kidney disease is dependent on the degree
of tubulointerstitial damage,11 amelioration of tubulointerstitial
lipotoxicity mediated by FFA could represent an additional
therapeutic target to prevent the progression of tubulointerstitial
lesion in proteinuric kidney disease.
Peroxisome proliferator-activated receptor (PPAR)-a is a
member of the nuclear hormone receptor superfamily of
ligand-activated transcription factors, and positively regulates
fatty acid b-oxidation, lipolysis, through the upregulation of
expression levels of several enzymes involved in lipolysis.12–14
PPARa exists in both glomerular and renal tubular cells, and
regulates renal lipolysis.15 Thus, the pharmacological activa-
tion of PPARa in the kidney may have a therapeutic potency
through its lipolytic effect against lipotoxicity—related both
to glomerular injury associated with metabolic abnormalities
and to tubulointerstitial injury in proteinuric kidney disease.
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In the present study, we investigated whether fenofibrate, a
PPARa agonist, attenuates glomerular injury in HFD-fed
obese mice and tubulointerstitial injury in a mouse model of
FFA-bound bovine serum albumin (BSA)-overload nephro-
pathy. In addition, we performed in vitro studies using
cultured mouse mesangial and proximal tubular cells to show
the direct renoprotective role of PPARa agonist. The results
showed that PPARa agonist attenuated lipotoxicity-mediated
oxidative stress and renal injury with enhancement of renal
lipolysis, suggesting its potential use in a new therapeutic
strategy against the initiation and progression of CKD.
RESULTS
Fenofibrate attenuates HFD-induced glomerular injury
At the end of the 12-week experimental period, treatment
of HFD-fed obese mice with fenofibrate significantly reduced
body weight, blood glucose, and plasma insulin levels,
without affecting the food intake (Table 1). Furthermore,
fenofibrate treatment significantly improved HFD-induced
insulin resistance determined by intraperitoneal insulin
tolerance test (Table 1). Fenofibrate treatment significantly
decreased the plasma levels of triglyceride, although it did not
affect the plasma levels of cholesterol and FFA (Table 1). No
significant difference in systolic blood pressure was observed
among all groups of mice (Table 1).
Next, we examined the effect of fenofibrate on HFD-
induced renal injury. Fenofibrate treatment significantly
attenuated the development of albuminuria in HFD-fed
mice (Table 1). Histologically, fenofibrate treatment signifi-
cantly attenuated HFD-induced increases of mesangial
matrix area (Figure 1a and b) and glomerular volume
(Figure 1a and c). Fenofibrate treatment also ameliorated
glomerular fibrosis determined by immunostaining for
fibronectin (Figure 1d and e), type I collagen (Figure 1f
and g), and type IV collagen (Figure 1h and i). Furthermore,
fenofibrate treatment significantly inhibited HFD-induced
increases of mRNA expression levels of fibronectin and
plasminogen activator inhibitor-1 (PAI-1) in the renal cortex,
both of which are indices of renal fibrosis (Table 2). Neither
HFD feeding nor fenofibrate treatment influenced PPARa
gene expression in the renal cortex (Table 2).
Fenofibrate enhances renal lipolysis and attenuates
oxidative stress in the kidney of HFD-fed mice
Oil-red O staining showed that fenofibrate treatment reduced
HFD-induced neutral lipid accumulation mainly in the
glomeruli (Figure 2a). Consistent with this result, feno-
fibrate significantly attenuated HFD-induced increase in
renal triglyceride content (Figure 2b). Immunohistochemical
analysis of 4-hydroxynonenal-modified proteins, a marker
of lipid peroxidation, showed that fenofibrate treat-
ment reduced 4-hydroxynonenal accumulation in glomeruli
(Figure 2c). Similarly, in the renal cortex of HFD-fed mice,
fenofibrate treatment significantly reduced the content of
malondialdehyde, which reflects the degree of lipid peroxida-
tion (Figure 2d). In addition, fenofibrate treatment signifi-
cantly increased the expression levels of lipolytic genes,
such as acyl-CoA oxidase (ACO), medium-chain acyl-CoA
dehydrogenase, and carnitine palmitoyltransferase-1
(CPT-1), in the kidney of HFD-fed mice (Table 2). These
changes in the expression levels of ACO and CPT-1 were
confirmed by western blot analysis (Figure 2e, f and g). Sterol
regulatory element-binding transcription factor-1c (SREBP-
1c) is a transcriptional factor regulating gene expression of
lipogenic enzymes such as acetyl-CoA carboxylase. Protein
expression of the active form of SREBP-1c tended to increase
in the kidney of HFD-fed mice, which was not affected by
fenofibrate treatment (Figure 2e and h). Accordingly, renal
protein and mRNA expression of acetyl-CoA carboxylase-a
in four groups of mice showed a similar tendency to the
Table 1 | Characteristics and results of IPITT at the end of 12-week experimental period in HFD model
LFD HFD
Control Fenofibrate Control Fenofibrate
Characteristics
Body weight (g) 30.2±0.46b 26.2±0.50b 45.6±1.09a 38.5±1.31a,b
Fasting blood glucose (mg/dl) 114.1±6.15b 114.8±5.52b 197.4±16.35a 124.6±7.55b
Plasma triglyceride (mg/dl) 62.0±7.8 44.4±2.6b 81.8±5.9 51.8±3.7b
Plasma cholesterol (mg/dl) 113.0±10.3b 119.2±3.4b 169.9±7.6a 156.5±16.4a
Plasma FFA (mEq/l) 1.02±0.11 0.79±0.10 0.70±0.04a 0.56±0.02a
Hemoglobin A1c (%) 3.1±0.12b 3.3±0.07b 3.9±0.08a 3.7±0.10
Plasma insulin (ng/ml) 0.32±0.16b 0.18±0.06b 1.47±0.38a 0.48±0.12b
Systolic blood pressure (mmHg) 106.4±4.9 94.6±7.5 113.5±4.6 109.1±2.3
Food intake (kcal/day) 11.2±0.69b 10.8±0.13b 15.1±0.42a 15.6±0.89a
Urinary albumin excretion (mg/day) 18.8±4.8b 6.0±1.0b 50.4±10.0a 20.2±4.6b
IPITT
Glucose level at basal (mg/dl) 142.5±9.5b 127.3±6.3b 261.5±31.4a 118.0±10.5b
Glucose level at 15min (mg/dl) 80.5±2.6b 75.8±7.4b 260.0±40.3a 71.0±6.6b
Glucose level at 30min (mg/dl) 63.8±5.0b 63.5±5.7b 221.3±37.3a 55.8±5.4b
Glucose level at 60min (mg/dl) 55.8±11.1b 69.8±7.0b 206.8±30.3a 60.8±7.2b
Abbreviations: FFA, free fatty acid; HFD, high-fat diet; IPITT, intraperitoneal insulin tolerance test; LFD, low-fat diet.
Data are mean±s.e.m.; n=8 (except for food intake and IPITT) in each group and n=4 (food intake and IPITT) in each group.
aPo0.05 versus mice fed LFD and bPo0.05 versus mice fed HFD.
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expression level of SREBP-1c (Figure 2e and i, Table 2). No
significant difference in renal expression of another tran-
scriptional regulator of lipogenesis, PPARg, was observed in
all groups (Table 2). Furthermore, fenofibrate signifi-
cantly increased the mRNA expression levels of antioxidant
genes, such as catalase, Cu/Zn-superoxide dismutase, and
Mn-superoxide dismutase, in the renal cortex of HFD-fed
mice (Table 2). Taken together, fenofibrate seems to attenuate
albuminuria and glomerular fibrosis in HFD-fed obese
mice, accompanied by enhancement of renal lipolysis and
antioxidant defenses.
Fenofibrate has antifibrotic action and attenuates oxidative
stress in cultured mesangial cells
We next investigated the mRNA expression of PAI-1 in
cultured mesangial cells stimulated by palmitate, a saturated
fatty acid, to determine the direct protective effect of
fenofibrate on lipotoxicity-mediated glomerular injury. In
mesangial cells, palmitate significantly increased the mRNA
expression level of PAI-1 (Figure 3a). Pretreatment with
fenofibrate significantly attenuated palmitate-induced over-
expression of PAI-1 in a dose-dependent manner (Figure 3a).
In addition, pretreatment with fenofibrate significantly
LF
D
H
FD
0
1000
2000
3000
4000
5000
G
lo
m
er
ul
ar
 v
ol
um
e 
(μm
2 )
0
200
400
600
800
1000
M
es
an
gi
al
 a
re
a 
(μm
2 )
0
1
2
4
Fi
br
on
ec
tin
 s
co
re 3
LF
D
LF
D
+f
en
o
H
FD
H
FD
+f
en
o
Feno (–)
PAS
LF
D
H
FD
LF
D
LF
D
+f
en
o
H
FD
H
FD
+f
en
o
LF
D
LF
D
+f
en
o
H
FD
H
FD
+f
en
o
* *
*
* *
*
* *
*
Feno (–)
Fibronectin
LF
D
H
FD
Feno (–)
Type I collagen
LF
D
H
FD
Feno (–)
Type IV collagen
0
1
2
4
Ty
pe
 I 
co
lla
ge
n 
sc
or
e
3
LF
D
LF
D
+f
en
o
H
FD
H
FD
+f
en
o
* *
*
0
1
2
4
Ty
pe
 IV
 c
ol
la
ge
n 
sc
or
e
3
LF
D
LF
D
+f
en
o
H
FD
H
FD
+f
en
o
* *
*
*
*
Feno (+)Feno (+)Feno (+)
Feno (+)
Figure 1 | Fenofibrate prevents HFD-induced glomerular injury. (a) Representative photomicrographs of periodic acid-Schiff (PAS)-
stained glomeruli in kidney sections in LFD-fed and HFD-fed mice with or without fenofibrate (LFD, LFDþ feno, HFD, and HFDþ feno).
Magnification  400. (b, c) Quantitative analysis of mesangial area (b) and glomerular volume (c) in 20 glomeruli per mouse. Data are
mean±s.e.m. of eight mice in each group. (d) Representative photomicrographs of glomeruli in kidney sections immunostained for
fibronectin in each group. Magnification  400. (e) Quantitative analysis of fibronectin score in 20 glomeruli per mouse. Data are
mean±s.e.m. of four mice in each group. (f) Representative photomicrographs of glomeruli in kidney sections immunostained for type I
collagen in each group. Magnification  400. (g) Quantitative analysis of type I collagen score in 20 glomeruli per mouse. Data are
mean±s.e.m. of four mice in each group. (h) Representative photomicrographs of glomeruli in kidney sections immunostained for type IV
collagen in each group. Magnification  400. (i) Quantitative analysis of type IV collagen score in 20 glomeruli per mouse. Data are
mean±s.e.m. of four mice in each group. *Po0.05. feno, fenofibrate; HFD, high-fat diet; LFD, low-fat diet.
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increased the mRNA expression levels of ACO and CPT-1 in
a dose-dependent manner, and tended to increase the mRNA
expression level of medium-chain acyl-CoA dehydrogenase in
palmitate-stimulated mesangial cells (Figure 3b–d). Further-
more, pretreatment with fenofibrate significantly reduced the
production of reactive oxygen species (ROS) in palmitate-
stimulated mesangial cells (Figure 3e).
Fenofibrate attenuates FFA-bound BSA-overload
tubulointerstitial injury
To determine whether PPARa agonist has a protective role
against tubulointerstitial lesion in proteinuric kidney disease,
we examined the effect of fenofibrate on FFA-bound BSA-
overload nephropathy model. Neither BSA overload nor
fenofibrate treatment influenced the systemic parameters at
the end of the experiment (Table 3). Fenofibrate treatment
tended to reduce proteinuria in FFA-bound BSA-overloaded
mice, although the effect was not significant (Table 3).
Morphological analysis of the kidneys of FFA-bound BSA-
overloaded mice showed tubular dilatation, tubular vacuo-
lation, and detachment of proximal tubular cells from
the tubular basement membrane and interstitial edema
(Figure 4a and b). Furthermore, the deposition of fibronectin
(Figure 4c and d), type I collagen (Figure 4e and f) and IV
collagen (Figure 4g and h), and infiltration of macrophages in
the interstitium (Figure 4i and j) were significantly increased
in the FFA-bound BSA-overloaded mice. Fenofibrate treat-
ment significantly attenuated these histological abnormalities
in the FFA-bound BSA-overloaded mice (Figure 4a–j).
Compatible with these morphological changes, FFA-bound
BSA-overload-induced increases in the mRNA expression
levels of fibronectin, PAI-1, and monocyte chemoattractant
protein-1 (MCP-1), a marker of inflammation, in the kidney
were significantly inhibited by fenofibrate treatment (Table 4).
The renal mRNA expression level of PPARa was significantly
decreased by FFA-bound BSA-overload, which was not
affected by fenofibrate treatment (Table 4).
Fenofibrate enhances renal lipolysis and attenuates
oxidative stress in FFA-bound BSA-overloaded mice
Immunohistochemical analysis showed that fenofibrate
treatment attenuated the FFA-bound BSA-overload-induced
increase in accumulation of 4-hydroxynonenal-modified pro-
teins in the renal interstitium (Figure 5a). Similarly, increased
renal malondialdehyde contents in FFA-bound BSA-over-
loaded mice were significantly reduced by fenofibrate
treatment (Figure 5b). Fenofibrate treatment increased the
mRNA expression levels of lipolytic enzymes such as ACO,
medium-chain acyl-CoA dehydrogenase, and CPT-1 in the
kidneys of both phosphate-buffered saline (PBS)-injected
and FFA-bound BSA-overloaded mice (Table 4). These
changes in the expression levels of ACO and CPT-1 were
confirmed by western blot analysis (Figure 5c–e). As for the
expression of renal lipogenic enzymes, significant changes in
protein and mRNA expression of lipogenic genes, such as
SREBP-1c, acetyl-CoA carboxylase-a and PPARg, were not
observed in the kidneys of all groups (Figure 5c, f and g,
Table 4). Furthermore, fenofibrate treatment did not affect
the mRNA expression levels of antioxidant genes in FFA-
bound BSA-overloaded mice (Table 4). These results indicate
that fenofibrate attenuates tubulointerstitial fibrosis and
inflammation, with enhancement of renal lipolysis in the
FFA-bound BSA-overloaded mice.
Fenofibrate has antifibrotic and anti-inflammatory effects,
and attenuates oxidative stress in cultured proximal tubular
cells
To examine the direct renoprotective effect of fenofibrate on
tubulointerstitial inflammation and fibrosis, we examined the
mRNA expression levels of MCP-1 and PAI-1 in palmitate-
stimulated cultured murine proximal tubular cells. Palmitate
stimulation significantly increased the mRNA expression
levels of MCP-1 and PAI-1 (Figure 6a and b). Pretreatment of
fenofibrate significantly attenuated the increased mRNA
expression levels of MCP-1 and PAI-1 (Figure 6a and b).
Similar to the results for mesangial cells, pretreatment with
fenofibrate significantly increased the mRNA expression
levels of ACO, medium-chain acyl-CoA dehydrogenase, and
CPT-1 in palmitate-stimulated proximal tubular cells (Figure
6c–e). Furthermore, pretreatment with fenofibrate signifi-
cantly reduced ROS production in palmitate-stimulated
proximal tubular cells (Figure 6f).
DISCUSSION
The present study showed that fenofibrate, a PPARa agonist,
attenuated glomerular injury in HFD-fed obese mice and
Table 2 | The mRNA expression levels in the renal cortex at
the end of 12-week experimental period in HFD model
LFD HFD
Control Fenofibrate Control Fenofibrate
Fibrosis
Fibronectin 0.95±0.12b 1.36±0.13 1.86±0.33a 0.98±0.14b
PAI-1 1.43±0.19b 0.88±0.11b 2.89±0.39a 1.00±0.16b
Lipolysis
PPARa 0.96±0.11 1.82±0.34 1.12±0.08 1.74±0.15
ACO 1.11±0.18 1.41±0.12 0.58±0.05 1.47±0.32b
MCAD 0.88±0.10 1.54±0.12a,b 0.58±0.03 1.39±0.20b
CPT-1 1.02±0.11 1.24±0.07 0.87±0.07 1.29±0.10b
Lipogenesis
ACCa 1.29±0.14 1.71±0.23 1.79±0.21 1.65±0.10
PPARg 0.72±0.09 0.84±0.08 0.88±0.06 0.70±0.11
Anti-oxidant
Catalase 0.91±0.08 0.92±0.05 0.84±0.06 1.26±0.09a,b
Cu/Zn-SOD 0.92±0.06 1.06±0.08 0.80±0.11 1.89±0.20a,b
Mn-SOD 0.86±0.04 1.19±0.13 1.04±0.06 1.54±0.12a,b
Abbreviations: ACC, acetyl-CoA carboxylase; ACO, acyl-CoA oxidase; CPT-1, carnitine
palmitoyltransferase-1; HFD, high-fat diet; LFD, low-fat diet; MCAD, medium-chain
acyl-CoA dehydrogenase; PAI-1, plasminogen activator inhibitor-1; PPAR, peroxi-
some proliferator-activated receptor; SOD, superoxide dismutase.
Data are mean±s.e.m.; n=6 in each group.
aPo0.05 versus mice fed LFD and bPo0.05 versus mice fed HFD.
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tubulointerstitial injury in FFA-bound BSA-overload nephro-
pathy mice. These renoprotective effects of fenofibrate were
accompanied by enhancement of renal lipolysis, which
consequently prevented lipid accumulation, oxidative stress,
fibrosis, and inflammation. These results highlight the
importance of PPARa-mediated enhancement of renal
lipolysis as novel therapeutic strategy for prevention of both
initiation and progression of CKD.
We have previously reported that mice with HFD-induced
obesity exhibit renal lesions similar to CKD in patients with
metabolic syndrome.6,16 The present study provided the first
evidence for the renobeneficial effects of fenofibrate against
albuminuria and glomerular lesions in HFD-fed mice.
PPARa is expressed in several organs, such as liver and
skeletal muscle. PPARa agonists induce lipolysis in these
metabolic organs and subsequently attenuate insulin resis-
tance in diet-induced obese model17 and type 2 diabetic
db/db mice,18 which was confirmed in our study. The present
study showed for the first time that fenofibrate could enhance
renal lipolysis as well as these metabolic organs. Furthermore,
recent reports showed that fenofibrate attenuated renal
injuries in spontaneously hypertensive rats fed a HFD19
and type 2 diabetic db/db mice,20 although the mechanisms
of the renoprotective effects of fenofibrate in these models
were not determined. As renal lipotoxicity is involved in the
pathogenesis of renal injury in these models,7,19 and based on
our results, amelioration of intrarenal lipotoxicity with
enhancement of renal lipolysis could explain the mechanism
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Figure 2 | Fenofibrate prevents HFD-induced lipid accumulation and oxidative stress in the glomeruli. (a) Representative
photomicrographs of oil-red O-stained glomeruli in kidney sections in LFD-fed and HFD-fed mice with or without fenofibrate. Magnification
 400. (b) Triglyceride contents in the renal cortex of mice in each group. Data are mean±s.e.m. of 4–7 mice in each group.
(c) Representative photomicrographs of glomeruli in kidney sections immunostained for 4-HNE in each group. Magnification  400.
(d) MDA contents in the renal cortex in each group. Data are mean±s.e.m. of six mice in each group. (e) Representative immunoblots of
ACO, CPT-1, SREBP-1, and ACC in protein extracted from the renal cortex of mice of each group. b-Actin was loaded as an internal control.
(f) Quantitative analysis of ACO protein expression. (g) Quantitative analysis of CPT-1 protein expression. (h) Quantitative analysis of SREBP-1
protein expression. (i) Quantitative analysis of ACC protein expression. Data are mean±s.e.m. of six mice in each group. *Po0.05. ACC,
acetyl-CoA carboxylase; ACO, acyl-CoA oxidase; CPT-1, carnitine palmitoyltransferase-1; feno, fenofibrate; HFD, high-fat diet; 4-HNE, 4-
hydroxynonenal; LFD, low-fat diet; MDA, malondialdehyde; SREBP-1, sterol regulatory element-binding protein-1.
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underlying fenofibrate-mediated renoprotective effects in
these models.
In proteinuric kidney disease regardless of the metabolic
disorder, tubulointerstitial damage, including fibrosis, proximal
tubular cell damage, and inflammation, is closely associated
with renal prognosis.21 The increased reabsorption of FFA-
bound albumin by proximal tubular cells has been confirmed as
the pathogenic process responsible for tubulointerstitial damage
in a FFA-bound BSA-overload nephropathy mouse model.9,10
FFA-bound BSA overload resulted in severer tubular damage in
PPARa-knockout22 and interleukin-18 receptor-knockout mice.23
However, no study has so far reported an effective therapeutic
approach against this type of renal injury. We showed here that
treatment with PPARa agonist, fenofibrate, improved tubu-
lointerstitial injury, with enhancement of lipolysis and reduction
of fibrosis, inflammation, and oxidative stress, suggesting that
activation of endogenous level of PPARa seems to have a
protective role against tubulointerstitial injury in proteinuric
kidney disease by mediating renal lipid homeostasis.
Overexpression of lipogenic enzymes24 and/or under-
expression of lipolytic enzymes25 in local tissues are reported
to be one cause of lipid accumulation and subsequent tissue
damage including renal injury. Thus, regulation of enzyme
expression associated with lipid metabolism may be a suitable
strategy against lipotoxicity-associated tissue dysfunction.
Several reports suggested that PPARa agonists enhance
lipolysis through upregulation of lipolytic enzymes, and thus
improve lipotoxicity-mediated tissue damage in the liver and
skeletal muscle.17,26 In the present study, we confirmed that
fenofibrate upregulated the expressions of lipolytic enzymes
in the kidney, although it did not affect the expression
levels of lipogenic enzymes. These results suggest that
fenofibrate-mediated renal lipolysis with overexpression of
lipolytic enzymes contributes to the improvement in renal
lipotoxicity.
Lipid-mediated oxidative stress is considered to induce
inflammation and fibrosis in the kidney. Accordingly,
amelioration of lipotoxicity-induced renal oxidative stress
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Figure 3 | Fenofibrate has an antifibrotic effect, enhances the expression of lipolytic enzymes, and reduces reactive oxygen species
(ROS) in palmitate-stimulated cultured mesangial cells. (a) Quantification of PAI-1 mRNA expression in cultured mesangial cells
stimulated by palmitate with or without pretreatment of fenofibrate at the indicated concentration (control, palmitate, palmitateþ feno10,
palmitateþ feno25, and palmitateþ feno50). Results are expressed as fold change relative to the mRNA of control. Data are mean±s.e.m.
(b–d) The mRNA expression levels of ACO (b), CPT-1 (c), and MCAD (d) in each group of mesangial cells. Data are mean±s.e.m.
(e) Intracellular production of ROS from mesangial cells in each group. The results are expressed in arbitrary units. Data are mean±s.e.m.
*Po0.05. ACO, acyl-CoA oxidase; CPT-1, carnitine palmitoyltransferase-1; DCF, 2.7-dichlorodihydrofluorescein; feno, fenofibrate; MCAD,
medium-chain acyl-CoA dehydrogenase; PAI-1, plasminogen activator inhibitor-1.
Table 3 | Characteristics at the end of experimental period in mice with FFA-bound BSA-overload model
PBS FFA-bound BSA
Control Fenofibrate Control Fenofibrate
Body weight (g) 22.9±0.52 22.5±0.42 23.7±0.25 23.4±0.58
Blood glucose (mg/dl) 159.2±9.0 142.0±11.3 141.0±8.1 137.5±11.3
Plasma insulin (ng/ml) 0.96±0.38 0.92±0.39 1.11±0.28 1.03±0.34
Urinary protein excretion (mg/day) 3.86±0.67 2.95±0.32 6.92±1.51 3.79±0.40
Abbreviations: BSA, bovine serum albumin; FFA, free fatty acid; PBS, phosphate-buffered saline.
Data are mean±s.e.m.; n=5 in each group.
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Figure 4 | Fenofibrate prevents free fatty acid (FFA)-bound bovine serum albumin (BSA)-induced interstitial lesion. (a) Representative
photomicrographs of hematoxylin and eosin-stained kidney sections in PBS-injected and FFA-bound BSA-injected mice with or without
fenofibrate (PBS, PBSþ feno, FFA-bound BSA, and FFA-bound BSAþ feno). Magnifications  200 and  400. (b) Quantitative analysis of
interstitial damage score from 20 random fields per mouse. Data are mean±s.e.m. of four mice in each group. (c) Representative
photomicrographs of kidney sections immunostained for fibronectin in each group. Magnification  100. (d) Quantitative analysis of fibronectin
score from 20 random fields per mouse. Data are mean±s.e.m. of four mice in each group. (e) Representative photomicrographs of kidney
sections immunostained for type I collagen in each group. Magnification  200. (f) Quantitative analysis of type I collagen score from 20 random
fields per mouse. Data are mean±s.e.m. of four mice in each group. (g) Representative photomicrographs of kidney sections immunostained for
type IV collagen in each group. Magnification  200. (h) Quantitative analysis of type IV collagen score from 20 random fields per mouse. Data are
mean±s.e.m. of four mice in each group. (i) Representative photomicrographs of kidney sections immunostained for F4/80 in each group.
Magnification  200. (j) Quantitative analysis of F4/80-positive cells from 20 random fields per mouse. Data are mean±s.e.m. of four mice in each
group. *Po0.05. feno, fenofibrate; PBS, phosphate-buffered saline.
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seems a conceivable therapy in CKD. In our in vivo
study, fenofibrate ameliorated lipotoxicity-associated ROS
accumulation in the kidneys of both HFD-fed obese mice and
FFA-bound BSA-overload nephropathy mice. Generally, ROS
accumulation occurs by an imbalance between ROS produc-
tion and antioxidant defenses. Also, PPARa positively
regulates the expression of genes associated with antioxidant
in addition to those involved in lipolysis.27 The present study
showed that fenofibrate increased renal expression levels of
lipolytic genes in both animal experimental models. In
contrast, it increased the expression of antioxidant enzymes
only in the kidney of HFD-fed mice, but not in FFA-bound
BSA-overloaded mice. Based on these findings, the enhance-
ment of renal lipolysis is more important for fenofibrate-
mediated reduction of ROS in both mouse experimental
models, although the strengthened antioxidant defenses may
partially contribute to fenofibrate-mediated renoprotection
in HFD model.
Our present study showed that FFA-bound BSA overload
decreased PPARa expression in the kidney. In this regard, the
previous study reported that FFA-bound BSA-overload
caused severe tubular damage in PPARa-deficient mice.22
These findings suggest that the decrease in renal PPARa
expression might contribute to the pathogenesis of FFA-
bound BSA-overload nephropathy. As for the role of
endogenous PPARa expression on glomerular injury, until
recently, there have been no reports showing the effect of
PPARa deficiency on glomerular injury associated with
metabolic disease. Based on the results from several previous
studies, PPARa-knockout mice do not develop obesity and
show hypoglycemia, even under a HFD.28 Also, HFD-induced
glomerular injury largely depends on systemic metabolic
abnormality, such as obesity and insulin resistance.6 Thus,
systemic PPARa-knockout mouse would not be a suitable
mouse model to conclude the exact role of renal PPARa
deficiency in glomerular injury associated with metabolic
disease. The experimental study using glomerular cell-specific
PPARa-knockout mouse may prove it, although this type of
mice model is not available now.
Interestingly, a recent clinical study showed the effective
therapeutic potency of fenofibrate in diabetic nephropathy.29
The Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) study showed that fenofibrate prevented the
initiation and progression of albuminuria in patients with
type 2 diabetes mellitus.29 Consistent with this result, our
results suggest that enhancement of renal lipolysis may be
involved in the mechanism underlying the renoprotective
effect of fenofibrate seen in the FIELD study.
In conclusion, our study demonstrated that fenofibrate
ameliorated the development of both glomerular lesion in
HFD-fed mice and tubulointerstitial lesion in FFA-bound
BSA-overload nephropathy mice, with enhancement of
renal lipolysis. These results provide evidence that pharma-
cological activation of PPARa could be a therapeutically
suitable strategy against glomerular and tubulointerstitial
lesions in CKD.
MATERIALS AND METHODS
Animal models
All procedures were performed in accordance with the guidelines of
the Research Center for Animal Life Science of Shiga University of
Medical Science.
HFD-induced renal injury model. Five-week-old male C57BL/6
mice were purchased from CLEA Japan (Tokyo, Japan), and housed
in cages and maintained on a 12-h light/12-h dark cycle. A low-fat
diet (LFD: 10% of total calories from fat) and a HFD (60% of total
calories from fat) were purchased from Research Diets (New
Brunswick, NJ). After 2 weeks of acclimatization, 7-week-old mice
were divided into four groups: LFD, LFDþ fenofibrate, HFD, and
HFDþ fenofibrate group (n¼ 13, 9, 13 and 8, respectively), and
received LFD, HFD, LFD, or HFD, respectively, supplemented with
fenofibrate (0.05% wt/wt)30,31 (Teijin Pharma, Tokyo, Japan) for
12 weeks. At the end of the 12-week experimental period, body
weight, blood glucose level, and systolic blood pressure16 were
measured, and an intraperitoneal insulin tolerance test6 was
performed. Mice were placed in metabolic balance cages for 24-h
urine collection. After the 24-h urine collection, mice were
anesthetized by intraperitoneal injection of pentobarbital sodium
(50mg/kg body weight), and then blood was drawn for biochemical
assay. The kidneys were removed as previous.16
FFA-bound BSA-induced renal injury model. Seven-week-old
male C57BL/6 mice were divided into four groups: PBS, PBSþ fe-
nofibrate, FFA-bound BSA, and FFA-bound BSAþ fenofibrate
group (n¼ 6, 6, 9, and 6, respectively). Mice were fed either a
standard diet or the same diet supplemented with fenofibrate
(0.05% wt/wt). At 3 days after the assignation to either diet, the mice
of each group were given consecutive daily intraperitoneal bolus
Table 4 | The mRNA expression levels in the kidney at the end
of experimental period in mice with FFA-bound BSA-overload
model
PBS FFA-bound BSA
Control Fenofibrate Control Fenofibrate
Fibrosis and inflammation
Fibronectin 1.04±0.18b 0.71±0.03b 1.62±0.13a 0.88±0.07b
PAI-1 0.61±0.11b 0.72±0.20b 1.53±0.13a 0.71±0.07b
MCP-1 0.55±0.13b 0.31±0.03b 1.50±0.24a 0.62±0.12b
Lipolysis
PPARa 1.61±0.26 1.85±0.10b 0.87±0.10a 1.14±0.171
ACO 1.20±0.16 1.71±0.21 1.06±0.15 3.06±0.57a,b
MCAD 1.16±0.16 1.25±0.06 0.85±0.09 1.73±0.16a,b
CPT-1 1.35±0.14 1.32±0.13 0.96±0.18 2.01±0.30b
Lipogenesis
ACCa 0.75±0.13 0.66±0.07 1.27±0.24 0.87±0.14
PPARg 0.72±0.09 0.84±0.08 0.88±0.06 0.70±0.11
Anti-oxidant
Catalase 1.22±0.13 0.97±0.03 0.82±0.04a 0.76±0.06a
Cu/Zn-SOD 1.00±0.02 1.27±0.24 1.35±0.31 1.01±0.10
Mn-SOD 0.99±0.11 0.99±0.08 1.01±0.16 1.00±0.13
Abbreviations: ACC, acetyl-CoA carboxylase; ACO, acyl-CoA oxidase; BSA, bovine
serum albumin; CPT-1, carnitine palmitoyltransferase-1; FFA, free fatty acid; MCP-1,
monocyte chemoattractant protein-1; MCAD, medium-chain acyl-CoA dehydrogen-
ase; PAI-1, plasminogen activator inhibitor-1; PBS, phosphate-buffered saline; PPAR,
peroxisome proliferator-activated receptor; SOD, superoxide dismutase.
Data are mean±s.e.m.; n=6 in each group.
aPo0.05 versus PBS and bPo0.05 versus FFA-bound BSA.
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injection of either 0.3 g/30 g body weight FFA-bound BSA (Sigma
Chemical, St Louis, MO) diluted in sterile PBS or equal volume of
sterile PBS as control for 11 days. After the injection of BSA or PBS
on day 11, urine was collected over 24 h. At the end of the
experiment, mice were anesthetized and perfused as reported
previously.16
Blood and urine analysis
Serum triglycerides and total cholesterol were measured using L type TG
H kit and Cholesterol E-test kit, respectively (Wako Chemicals, Osaka,
Japan). Serum FFA level was determined using nonesterified fatty acid
C-test kit (Wako Chemicals). Hemoglobin A1c was measured using the
DCA 2000 analyzer (Siemens Medical Solutions Diagnostics, Tokyo,
Japan). Plasma insulin was measured using an ELISA kit (Morinaga
Institute of Biological Science, Tokyo, Japan). Urinary albumin and
urinary protein concentration were measured with an ELISA kit (Exocell,
Philadelphia, PA) and Bradford method, respectively.
Histological and immunohistochemical analyses
Fixed kidneys embedded in paraffin were sectioned (3-mm
thickness). Semiquantitative histological analysis for glomerular
lesions was performed using periodic acid-Schiff-stained sections, as
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Figure 5 | Fenofibrate prevents the increase of oxidative stress in the kidney of free fatty acid (FFA)-bound bovine serum albumin
(BSA)-overload nephropathy. (a) Representative photomicrographs of kidney sections immunostained for 4-HNE in PBS-injected and
FFA-bound BSA-injected mice with or without fenofibrate. Magnifications  40 and  200. (b) MDA contents in the kidney in each group.
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(e) Quantitative analysis of CPT-1 protein expression. (f) Quantitative analysis of SREBP-1 protein expression. (g) Quantitative analysis of ACC
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reported previously.16 Semiquantitative histological analysis for
interstitial lesion was performed using hematoxylin and eosin-
stained sections as reported previously.32
Immunohistochemical staining was performed with F4/80-
specific monoclonal anti-rat antibody (Serotec, Oxford, UK),
fibronectin-specific polyclonal anti-rabbit antibody (Chemicon
International, Temecula, CA), type I collagen-specific polyclonal
anti-goat antibody (Southern Biotech, Birmingham, AL), type IV
collagen-specific polyclonal anti-rabbit antibody (Millipore,
Billerica, MA), and 4-hydroxy-2-nonenal monoclonal anti-mouse
antibody (JaICA, Shizuoka, Japan). For evaluation of immunostain-
ing for fibronectin, the percentages of area stained for fibronectin
were graded as follows: grade 0, staining absent to 5%; grade 1,
5–25%; grade 2, 25–50%; grade 3, 50–75%; and grade 4, 475%.6
For evaluation of immunostaining for type I collagen and type IV
collagen, changes in the extent and the intensity of staining
were rated using the following grades: grade 0, no; grade 1, minor;
grade 2, moderate; grade 3, severe; and grade 4, most severe changes.
For evaluation of immunostaining for F4/80, F4/80-positive cells
were counted in 20 randomly selected areas.16 Accumulation of
neutral lipids was evaluated using 4-mm-thick oil-red O-stained
frozen sections.6
Lipid extraction and measurement of triglyceride
concentration
Total lipid was extracted from the renal cortex in HFD model and
from the kidney in BSA model by the method of Bligh and Dyer.33
Triglyceride contents were determined as described previously.6
Measurement of lipid peroxidation
The extent of lipid peroxidation was measured by the thiobarbituric
acid reactive substances assay using malondialdehyde assay kit
(JaICA). The malondialdehyde concentration was normalized to the
protein concentration.
Protein extraction and western blot analysis
The renal cortex in HFD model and the kidney in BSA model were
homogenized in an ice-cold lysis buffer containing 150mmol/l
NaCl, 50mmol/l Tris-HCl (pH 8.0), 0.1% SDS, 1% Nonidet P-40,
and protease inhibitor cocktail (Boehringer Mannheim, Lewes, UK).
These samples were resolved by 10% SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene fluoride mem-
branes (Immobilon, Bedford, MA). The membranes were incubated
with ACO-specific polyclonal anti-rabbit antibody (Abcam,
Cambridge, UK), CPT-1-specific polyclonal anti-goat antibody
(Santa Cruz Biotechnology, Santa Cruz, CA), SREBP-1-specific
monoclonal anti-mouse antibody (Thermo Fisher Scientific,
Waltham, MA), and acetyl-CoA carboxylase-specific monoclonal
anti-rabbit antibody (Cell Signaling Technology, Beverly, MA),
washed and incubated with horseradish peroxidase-coupled
secondary antibodies (Amersham, Buckinghamshire, UK). The
blots were visualized by using an enhanced chemiluminescence
detection system (Perkin Elmer Life Science, Boston, MA).
Mouse mesangial and proximal tubular cells
SV40-transformed murine mesangial cell line and murine proximal
tubular cell line were cultured as described previously.34,35 First, we
confirmed that the dose of fenofibrate we used in this experiment
was not cytotoxic in both cells using AlamarBlue Assay (Alamar
Bioscience, Sacramento, CA; data not shown). Next, we confirmed
that among several FFAs, including palmitate (a saturated fatty
acid), oleate (a monounsaturated fatty acid), eicosapentaenoic acid
(an o-3 polyunsaturated fatty acid), and linoleate (an o-6
polyunsaturated fatty acid), only palmitate increased the mRNA
m
R
N
A 
ex
pr
es
sio
n
(fo
ld 
ch
an
ge
 to
 co
ntr
ol)
PAI-1
MCAD
ACO
CPT-1
MCP-1
0
1
2
2.5
1.5
0
1
2
1.5
0.5
0
1
2
1.5
0.5
0
0.5
1
1.5
0.5
0
1
2
2.5
1.5
0.5
m
R
N
A 
ex
pr
es
sio
n
(fo
ld 
ch
an
ge
 to
 co
ntr
ol)
m
R
N
A 
ex
pr
es
sio
n
(fo
ld 
ch
an
ge
 to
 co
ntr
ol)
m
R
N
A 
ex
pr
es
sio
n
(fo
ld 
ch
an
ge
 to
 co
ntr
ol)
m
R
N
A 
ex
pr
es
sio
n
(fo
ld 
ch
an
ge
 to
 co
ntr
ol)
*
*
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
*
*
D
CF
 fl
uo
re
sc
en
ce
 
(ar
bit
rar
y u
nit
s)
3000
4000
5000
2000
1000
0
*
*
*
*
Control
Palmitate
Palmitate+feno (10 μmol/l)
Palmitate+feno (25 μmol/l)
Palmitate+feno (50 μmol/l)
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expression level of PAI-1 and MCP-1 in both cells (data not shown).
Then, to evaluate the effect of fenofibrate on lipotoxicity-associated
fibrosis and inflammation, subconfluent cultured cells were serum
starved for 24 h in the presence or absence of fenofibrate (dissolved
in dimethyl sulfoxide) at a final concentration of 10, 25, and
50 mmol/l, followed by stimulation with 200mmol/l of palmitate
(Sigma Chemical) in 8.0% BSA or same concentration of BSA, as
control for 12 h.
RNA extraction and quantitative real-time PCR
Total RNA was isolated from the kidney or cultured renal cells, and
cDNAwas synthesized as described previously.16 The iQSYBR Green
Supermix (Bio-Rad Laboratories, Hercules, CA) was used for real-
time PCR (ABI Prism TM 7500 Sequence Detection System; Perkin-
Elmer Applied Biosystems, Foster City, CA). The expression levels
of mRNAs were quantified using the standard curve method,
as reported previously.16 Analytical data were adjusted, with the
expression level of mRNA of b-actin as an internal control. Primer
sequences are described in Table 5.
Measurement of intracellular ROS
ROS generation was measured with fluoroprobe 2.7-dichlorodihy-
drofluorescein diacetate (Molecular Probes, Eugene, OR), which is
taken up by the cell and converted by intracellular esterases to 2.7-
dichlorodihydrofluorescein. ROS generation was evaluated as the
fluorescence intensity (excitation wavelength 488 nm and emission
wavelength 525 nm) of 2.7-dichlorodihydrofluorescein by an Infinite
M200 microplate reader (Tecan Japan, Kanagawa, Japan) after 3 h of
palmitate stimulation. The results of intracellular ROS generation
are expressed in arbitrary units.
Statistical analysis
Results are expressed as mean±s.e.m. Analysis of variance with
subsequent Scheffe test was used to determine the significance of
differences in multiple comparisons. A P-value o0.05 was consi-
dered statistically significant.
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Table 5 | Sequences of primers used for real-time PCR
Primer Forward Reverse
b-Actin CGTGCGTGACATCAAAGAGAA TGGATGCCACAGGATTCCAT
Fibronectin AGACCATACCTGCCGAATGTAG GAGAGCTTCCTGTCCTGTAGAG
PAI-1 GGACACCCTCAGCATGTTCA TCTGATGAGTTCAGCATCCAAGAT
MCP-1 GCCCCACTCACCTGCTGCTACT CCTGCTGCTGGTGATCCTCTTGT
PPARa ATGCCAGTACTGCCGTTTTC CCGAATCTTTCAGGTCGTGT
ACO GGCCAACTATGGTGGACATCA ACCAATCTGGCTGCTGCACGAA
MCAD TAATCGGTGAAGGAGCAGGTTT GGCATACTTCGTGGCTTCGT
CPT-1 ACCACTGGCCGAATGTCAAG AGCGAGTAGCGCATGGTCAT
ACCa CCCAGCAGAATAAAGCTACTTTGG TCCTTTTGTGCAACTAGGAACGT
PPARg CCAGAGTCTGCTGATCTGC GCCACCTCTTTGCTCTGCTC
Catalase GCCAGAAGAGAAACCCACAGA ACAAGAAAGAAACCTGATGGAGAGA
Cu/Zn-SOD AATGGTGGTCCATGAGAAACAAG GCAATCCCAATCACTCCACA
Mn-SOD CTTCAATAAGGAGCAAGGTCGC CACACGTCAATCCCCAGC
Abbreviations: ACC, acetyl-CoA carboxylase; ACO, acyl-CoA oxidase; CPT-1, carnitine palmitoyltransferase-1; MCAD, medium-chain acyl-CoA dehydrogenase; MCP-1,
monocyte chemoattractant protein-1; PAI-1, plasminogen activator inhibitor-1; PPAR, peroxisome proliferator-activated receptor; SOD, superoxide dismutase.
Kidney International (2011) 79, 871–882 881
Y Tanaka et al.: Renoprotective effects of fenofibrate against lipotoxicity o r ig ina l a r t i c l e
17. Nagai Y, Nishio Y, Nakamura T et al. Amelioration of high fructose-
induced metabolic derangements by activation of PPARalpha.
Am J Physiol Endocrinol Metab 2002; 282: E1180–E1190.
18. Koh E, Kim M, Park J et al. Peroxisome proliferator-activated receptor
(PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with
PPAR-gamma activation. Diabetes 2003; 52: 2331–2337.
19. Shin S, Lim J, Chung S et al. Peroxisome proliferator-activated receptor-alpha
activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in
spontaneously hypertensive rats. Hypertens Res 2009; 32: 835–845.
20. Park C, Zhang Y, Zhang X et al. PPARalpha agonist fenofibrate improves
diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511–1517.
21. Perico N, Codreanu I, Schieppati A et al. Pathophysiology of disease
progression in proteinuric nephropathies. Kidney Int Suppl 2005; 67: S79–S82.
22. Kamijo Y, Hora K, Kono K et al. PPARalpha protects proximal tubular cells
from acute fatty acid toxicity. J Am Soc Nephrol 2007; 18: 3089–3100.
23. Sugiyama M, Kinoshita K, Kishimoto K et al. Deletion of IL-18 receptor
ameliorates renal injury in bovine serum albumin-induced
glomerulonephritis. Clin Immunol 2008; 128: 103–108.
24. Ishigaki N, Yamamoto T, Shimizu Y et al. Involvement of glomerular
SREBP-1c in diabetic nephropathy. Biochem Biophys Res Commun 2007;
364: 502–508.
25. Fan C, Pan J, Usuda N et al. Steatohepatitis, spontaneous peroxisome
proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA
oxidase. Implications for peroxisome proliferator-activated receptor alpha
natural ligand metabolism. J Biol Chem 1998; 273: 15639–15645.
26. Zhao Z, Lee YJ, Kim SK et al. Rosiglitazone and fenofibrate improve insulin
sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in
the liver and skeletal muscle. Life Sci 2009; 84: 688–695.
27. Toyama T, Nakamura H, Harano Y et al. PPARalpha ligands activate
antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem
Biophys Res Commun 2004; 324: 697–704.
28. Guerre-Millo M, Rouault C, Poulain P et al. PPAR-alpha-null mice are
protected from high-fat diet-induced insulin resistance. Diabetes 2001;
50: 2809–2814.
29. Keech A, Simes R, Barter P et al. Effects of long-term fenofibrate therapy
on cardiovascular events in 9795 people with type 2 diabetes mellitus
(the FIELD study): randomised controlled trial. Lancet 2005; 366:
1849–1861.
30. Guerre-Millo M, Gervois P, Raspe´ E et al. Peroxisome proliferator-activated
receptor alpha activators improve insulin sensitivity and reduce adiposity.
J Biol Chem 2000; 275: 16638–16642.
31. Jeong S, Han M, Lee H et al. Effects of fenofibrate on high-fat
diet-induced body weight gain and adiposity in female C57BL/6J mice.
Metabolism 2004; 53: 1284–1289.
32. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-
acting erythropoietin analogue darbepoetin alpha persistently activates
endothelial Akt and attenuates progressive organ failure. Circulation
2004; 110: 1006–1012.
33. Bligh E, Dyer W. A rapid method of total lipid extraction and purification.
Can J Biochem Physiol 1959; 37: 911–917.
34. Kume S, Haneda M, Kanasaki K et al. SIRT1 inhibits transforming growth
factor beta-induced apoptosis in glomerular mesangial cells via Smad7
deacetylation. J Biol Chem 2007; 282: 151–158.
35. Takaya K, Koya D, Isono M et al. Involvement of ERK pathway in albumin-
induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol
Renal Physiol 2003; 284: F1037–F1045.
882 Kidney International (2011) 79, 871–882
or ig ina l a r t i c l e Y Tanaka et al.: Renoprotective effects of fenofibrate against lipotoxicity
